Your browser doesn't support javascript.
loading
Simulating Progression-Free and Overall Survival for First-Line Doublet Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients Based on Real-World Registry Data.
Degeling, Koen; Wong, Hui-Li; Koffijberg, Hendrik; Jalali, Azim; Shapiro, Jeremy; Kosmider, Suzanne; Wong, Rachel; Lee, Belinda; Burge, Matthew; Tie, Jeanne; Yip, Desmond; Nott, Louise; Khattak, Adnan; Lim, Stephanie; Caird, Susan; Gibbs, Peter; IJzerman, Maarten.
Affiliation
  • Degeling K; Health Technology and Services Research Department, Faculty of Behavioural, Management and Social Sciences, Technical Medical Centre, University of Twente, Enschede, The Netherlands. koen.degeling@unimelb.edu.au.
  • Wong HL; Cancer Health Services Research, School of Population and Global Health, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, VIC, Australia. koen.degeling@unimelb.edu.au.
  • Koffijberg H; Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
  • Jalali A; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Shapiro J; Health Technology and Services Research Department, Faculty of Behavioural, Management and Social Sciences, Technical Medical Centre, University of Twente, Enschede, The Netherlands.
  • Kosmider S; Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
  • Wong R; Department of Medical Oncology, Cabrini Health, Melbourne, VIC, Australia.
  • Lee B; Department of Medical Oncology, Western Health, Melbourne, VIC, Australia.
  • Burge M; Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
  • Tie J; Department of Medical Oncology, Eastern Health, Melbourne, VIC, Australia.
  • Yip D; Eastern Health Clinical School, Monash University, Box Hill, VIC, Australia.
  • Nott L; Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
  • Khattak A; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Lim S; Department of Medical Oncology, Northern Health, Melbourne, VIC, Australia.
  • Caird S; Department of Medical Oncology, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.
  • Gibbs P; Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
  • IJzerman M; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Pharmacoeconomics ; 38(11): 1263-1275, 2020 11.
Article in En | MEDLINE | ID: mdl-32803720
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Colorectal Neoplasms / Bevacizumab Type of study: Clinical_trials / Prognostic_studies Limits: Humans Language: En Journal: Pharmacoeconomics Journal subject: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Year: 2020 Document type: Article Affiliation country: Netherlands
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Colorectal Neoplasms / Bevacizumab Type of study: Clinical_trials / Prognostic_studies Limits: Humans Language: En Journal: Pharmacoeconomics Journal subject: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Year: 2020 Document type: Article Affiliation country: Netherlands